Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. (Q48723188)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

relapsing-remitting multiple sclerosis

19 January 2020

main subject

0 references

phase II clinical trial

0 references

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Xavier Montalban

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1

David H Miller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Richard Grove

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Claire Wardell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Joseph Horrigan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ole Graff

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Gillian Atkinson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Pinky Dua

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Tarek Yousry

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

David Macmanus

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

5 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

131-139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

1 reference

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

Role for tumor necrosis factor-α in JC virus reactivation and progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970299-X

7 January 2021

10.1016/S1474-4422(11)70299-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22226929%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference